Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03596281
Title Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV)
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

peritoneal carcinoma

fallopian tube carcinoma

ovary epithelial cancer

Therapies

Pegylated liposomal-doxorubicin + Pembrolizumab

Bevacizumab + Pembrolizumab

Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.